CNS Pharmaceuticals, Inc. Proceeds from Issuance of Private Placement
CNS Pharmaceuticals, Inc. (CNSP) reported Proceeds from Issuance of Private Placement of $22.50 million for the 0-month period ending 2026-05-05, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-12
- 2026-05-05: Proceeds from Issuance of Private Placement 0 month $22.50M.
- 2024-01-29: Proceeds from Issuance of Private Placement 0 month $3.33M.
| Period end | Proceeds from Issuance of Private Placement 0 month |
|---|---|
| 2026-05-05 | $22.50M 10-Q · filed 2026-08-12 |
| 2024-01-29 | $3.33M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |